{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:47:47Z","timestamp":1790423267108,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11886-022-01735-z","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T05:03:06Z","timestamp":1657947786000},"page":"1189-1195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Update on the Genetics of Primary Aldosteronism and Aldosterone-Producing Adenomas"],"prefix":"10.1007","volume":"24","author":[{"given":"Georgia","family":"Pitsava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7959-9842","authenticated-orcid":false,"given":"Fabio R.","family":"Faucz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine A.","family":"Stratakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Hannah-Shmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,16]]},"reference":[{"issue":"9859","key":"1735_CR1","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","volume":"380","author":"SS Lim","year":"2012","unstructured":"Lim SS, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(12)61766-8.","journal-title":"Lancet"},{"issue":"1","key":"1735_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"Brown JM, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020;173(1):10\u201320. https:\/\/doi.org\/10.7326\/M20-0065.","journal-title":"Ann Intern Med"},{"issue":"14","key":"1735_CR3","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1735_CR4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.mcna.2021.06.007","volume":"105","author":"N El-Asmar","year":"2021","unstructured":"El-Asmar N, Rajpal A, Arafah BM. Primary Hyperaldosteronism: Approach to Diagnosis and Management. Med Clin North Am. 2021;105(6):1065\u201380. https:\/\/doi.org\/10.1016\/j.mcna.2021.06.007.","journal-title":"Med Clin North Am"},{"issue":"11","key":"1735_CR5","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293\u2013300. https:\/\/doi.org\/10.1016\/j.jacc.2006.07.059.","journal-title":"J Am Coll Cardiol"},{"key":"1735_CR6","unstructured":"Fountain JH, Lappin SL. Physiology, Renin Angiotensin System. In StatPearls. Treasure Island (FL). 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470410\/. Accessed 6 Jun 2022"},{"issue":"11","key":"1735_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0337-9","volume":"51","author":"E Seidel","year":"2019","unstructured":"Seidel E, Schewe J, Scholl UI. Genetic causes of primary aldosteronism. Exp Mol Med. 2019;51(11):1\u201312. https:\/\/doi.org\/10.1038\/s12276-019-0337-9.","journal-title":"Exp Mol Med"},{"issue":"2","key":"1735_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1152\/physrev.00030.2003","volume":"84","author":"A Spat","year":"2004","unstructured":"Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84(2):489\u2013539. https:\/\/doi.org\/10.1152\/physrev.00030.2003.","journal-title":"Physiol Rev"},{"key":"1735_CR9","doi-asserted-by":"publisher","unstructured":"Funder JW, et al.\u00a0The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u20131916. https:\/\/doi.org\/10.1210\/jc.2015-4061.","DOI":"10.1210\/jc.2015-4061"},{"key":"1735_CR10","unstructured":"Conn JW.\u00a0Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med.\u00a01955;45(1):3\u201317."},{"issue":"8","key":"1735_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2005.01.015.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1735_CR12","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero P, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826\u201333. https:\/\/doi.org\/10.1210\/jc.2013-2805.","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR13","doi-asserted-by":"publisher","unstructured":"Funder JW, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266\u20133281.\u00a0https:\/\/doi.org\/10.1210\/jc.2008-0104.","DOI":"10.1210\/jc.2008-0104"},{"issue":"5","key":"1735_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"WF Young","year":"2007","unstructured":"Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607\u201318. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02775.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1735_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.632543","volume":"12","author":"CDC Kamilaris","year":"2021","unstructured":"Kamilaris CDC, Stratakis CA, Hannah-Shmouni F. Molecular Genetic and Genomic Alterations in Cushing\u2019s Syndrome and Primary Aldosteronism. Front Endocrinol (Lausanne). 2021;12: 632543. https:\/\/doi.org\/10.3389\/fendo.2021.632543.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1735_CR16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/ng.2695","volume":"45","author":"UI Scholl","year":"2013","unstructured":"Scholl UI, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45(9):1050\u20134. https:\/\/doi.org\/10.1038\/ng.2695.","journal-title":"Nat Genet"},{"key":"1735_CR17","doi-asserted-by":"publisher","unstructured":"Beuschlein F, et al.\u00a0Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet.\u00a02013;45(4):440\u20134, 444e1\u20132. https:\/\/doi.org\/10.1038\/ng.2550.","DOI":"10.1038\/ng.2550"},{"issue":"9","key":"1735_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ng.2716","volume":"45","author":"EA Azizan","year":"2013","unstructured":"Azizan EA, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45(9):1055\u201360. https:\/\/doi.org\/10.1038\/ng.2716.","journal-title":"Nat Genet"},{"issue":"2","key":"1735_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","volume":"64","author":"FL Fernandes-Rosa","year":"2014","unstructured":"Fernandes-Rosa FL, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension. 2014;64(2):354\u201361. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03419.","journal-title":"Hypertension"},{"issue":"3","key":"1735_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","volume":"50","author":"FL Fernandes-Rosa","year":"2018","unstructured":"Fernandes-Rosa FL, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet. 2018;50(3):355\u201361. https:\/\/doi.org\/10.1038\/s41588-018-0053-8.","journal-title":"Nat Genet"},{"issue":"8","key":"1735_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","volume":"138","author":"JB Byrd","year":"2018","unstructured":"Byrd JB, Turcu AF, Auchus RJ. Primary Aldosteronism: Practical Approach to Diagnosis and Management. Circulation. 2018;138(8):823\u201335. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033597.","journal-title":"Circulation"},{"issue":"1","key":"1735_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1161\/HYPERTENSIONAHA.117.09057","volume":"70","author":"GC Tan","year":"2017","unstructured":"Tan GC, et al. Aldosterone-Producing Adenomas: Histopathology-Genotype Correlation and Identification of a Novel CACNA1D Mutation. Hypertension. 2017;70(1):129\u201336. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09057.","journal-title":"Hypertension"},{"issue":"1","key":"1735_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1161\/HYPERTENSIONAHA.113.01733","volume":"63","author":"TA Williams","year":"2014","unstructured":"Williams TA, et al. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension. 2014;63(1):188\u201395. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01733.","journal-title":"Hypertension"},{"issue":"3","key":"1735_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/HYPERTENSIONAHA.119.14349","volume":"75","author":"K Nanba","year":"2020","unstructured":"Nanba K, et al. Somatic CACNA1H Mutation As a Cause of Aldosterone-Producing Adenoma. Hypertension. 2020;75(3):645\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14349.","journal-title":"Hypertension"},{"issue":"6018","key":"1735_CR25","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.1198785","volume":"331","author":"M Choi","year":"2011","unstructured":"Choi M, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768\u201372. https:\/\/doi.org\/10.1126\/science.1198785.","journal-title":"Science"},{"issue":"7","key":"1735_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041926","volume":"7","author":"T Akerstrom","year":"2012","unstructured":"Akerstrom T, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS ONE. 2012;7(7): e41926. https:\/\/doi.org\/10.1371\/journal.pone.0041926.","journal-title":"PLoS ONE"},{"issue":"3","key":"1735_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1161\/HYPERTENSIONAHA.111.186478","volume":"59","author":"S Boulkroun","year":"2012","unstructured":"Boulkroun S, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension. 2012;59(3):592\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.186478.","journal-title":"Hypertension"},{"issue":"8","key":"1735_CR28","doi-asserted-by":"publisher","first-page":"E1089","DOI":"10.1210\/jc.2015-2149","volume":"100","author":"L Lenzini","year":"2015","unstructured":"Lenzini L, et al. A Meta-Analysis of Somatic KCNJ5 K(+) Channel Mutations In 1636 Patients With an Aldosterone-Producing Adenoma. J Clin Endocrinol Metab. 2015;100(8):E1089\u201395. https:\/\/doi.org\/10.1210\/jc.2015-2149.","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR29","doi-asserted-by":"publisher","unstructured":"Rossi GP, et al.\u00a0KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. J Hypertens.\u00a02014;32(7):1514\u201321; discussion 1522. https:\/\/doi.org\/10.1097\/HJH.0000000000000186.","DOI":"10.1097\/HJH.0000000000000186"},{"issue":"2","key":"1735_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5551\/jat.24455","volume":"22","author":"T Kitamoto","year":"2015","unstructured":"Kitamoto T, et al. Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas. J Atheroscler Thromb. 2015;22(2):191\u2013200. https:\/\/doi.org\/10.5551\/jat.24455.","journal-title":"J Atheroscler Thromb"},{"key":"1735_CR31","doi-asserted-by":"publisher","unstructured":"\u2022 Chang YY, et al.\u00a0KCNJ5 Somatic Mutations in Aldosterone-Producing Adenoma Are Associated With a Worse Baseline Status and Better Recovery of Left Ventricular Remodeling and Diastolic Function. Hypertension.\u00a02021;77(1):114\u2013125.\u00a0https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15679. The findings of this study are important considerations in the management of patients with aldosterone-producing adenomas.","DOI":"10.1161\/HYPERTENSIONAHA.120.15679"},{"issue":"3","key":"1735_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/HJH.0000000000001578","volume":"36","author":"T Kitamoto","year":"2018","unstructured":"Kitamoto T, et al. KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma. J Hypertens. 2018;36(3):619\u201327. https:\/\/doi.org\/10.1097\/HJH.0000000000001578.","journal-title":"J Hypertens"},{"issue":"12","key":"1735_CR33","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1210\/en.2015-1466","volume":"156","author":"J Stindl","year":"2015","unstructured":"Stindl J, et al. Pathogenesis of Adrenal Aldosterone-Producing Adenomas Carrying Mutations of the Na(+)\/K(+)-ATPase. Endocrinology. 2015;156(12):4582\u201391. https:\/\/doi.org\/10.1210\/en.2015-1466.","journal-title":"Endocrinology"},{"issue":"6","key":"1735_CR34","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1210\/en.2015-2029","volume":"157","author":"P Tauber","year":"2016","unstructured":"Tauber P, et al. Cellular Pathophysiology of an Adrenal Adenoma-Associated Mutant of the Plasma Membrane Ca(2+)-ATPase ATP2B3. Endocrinology. 2016;157(6):2489\u201399. https:\/\/doi.org\/10.1210\/en.2015-2029.","journal-title":"Endocrinology"},{"issue":"10","key":"1735_CR35","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2018-01004","volume":"103","author":"K Nanba","year":"2018","unstructured":"Nanba K, et al. Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans. J Clin Endocrinol Metab. 2018;103(10):3869\u201376. https:\/\/doi.org\/10.1210\/jc.2018-01004.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1735_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/cen.12873","volume":"83","author":"UI Scholl","year":"2015","unstructured":"Scholl UI, et al. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin Endocrinol (Oxf). 2015;83(6):779\u201389. https:\/\/doi.org\/10.1111\/cen.12873.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1735_CR37","doi-asserted-by":"publisher","unstructured":"Nanba K, et al.\u00a0Prevalence of Somatic Mutations in Aldosterone-Producing Adenomas in Japanese Patients. J Clin Endocrinol Metab.\u00a02020;105(11). https:\/\/doi.org\/10.1210\/clinem\/dgaa595.","DOI":"10.1210\/clinem\/dgaa595"},{"issue":"4","key":"1735_CR38","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","volume":"72","author":"K Omata","year":"2018","unstructured":"Omata K, et al. Cellular and Genetic Causes of Idiopathic Hyperaldosteronism. Hypertension. 2018;72(4):874\u201380. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11086.","journal-title":"Hypertension"},{"key":"1735_CR39","doi-asserted-by":"publisher","unstructured":"Scholl UI, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015;4:e06315.\u00a0https:\/\/doi.org\/10.7554\/eLife.06315.","DOI":"10.7554\/eLife.06315"},{"issue":"3","key":"1735_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","volume":"50","author":"UI Scholl","year":"2018","unstructured":"Scholl UI, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet. 2018;50(3):349\u201354. https:\/\/doi.org\/10.1038\/s41588-018-0048-5.","journal-title":"Nat Genet"},{"issue":"5","key":"1735_CR41","doi-asserted-by":"publisher","first-page":"K37","DOI":"10.1530\/EJE-19-0377","volume":"181","author":"RK Dutta","year":"2019","unstructured":"Dutta RK, et al. A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma. Eur J Endocrinol. 2019;181(5):K37\u201341. https:\/\/doi.org\/10.1530\/EJE-19-0377.","journal-title":"Eur J Endocrinol"},{"key":"1735_CR42","doi-asserted-by":"publisher","unstructured":"Rege J, et al.\u00a0Identification of Somatic Mutations in CLCN2 in Aldosterone-Producing Adenomas. J Endocr Soc.\u00a02020;4(10):bvaa123. https:\/\/doi.org\/10.1210\/jendso\/bvaa123.","DOI":"10.1210\/jendso\/bvaa123"},{"issue":"2","key":"1735_CR43","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1365-2265.2007.03033.x43","volume":"68","author":"M Tadjine","year":"2008","unstructured":"Tadjine M, et al. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf). 2008;68(2):264\u201370. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03033.x43.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1735_CR44","doi-asserted-by":"publisher","unstructured":"Shimada H, et al.\u00a0Molecular Mechanisms of Functional Adrenocortical Adenoma and Carcinoma: Genetic Characterization and Intracellular Signaling Pathway. Biomedicines.\u00a02021;9(8). https:\/\/doi.org\/10.3390\/biomedicines9080892.","DOI":"10.3390\/biomedicines9080892"},{"issue":"8","key":"1735_CR45","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1210\/jc.2016-1700","volume":"101","author":"Y Rhayem","year":"2016","unstructured":"Rhayem Y, et al. PRKACA Somatic Mutations Are Rare Findings in Aldosterone-Producing Adenomas. J Clin Endocrinol Metab. 2016;101(8):3010\u20137. https:\/\/doi.org\/10.1210\/jc.2016-1700.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1735_CR46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1507\/endocrj.EJ15-0642","volume":"63","author":"Y Nakajima","year":"2016","unstructured":"Nakajima Y, et al. GNAS mutations in adrenal aldosterone-producing adenomas. Endocr J. 2016;63(2):199\u2013204. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0642.","journal-title":"Endocr J"},{"issue":"6","key":"1735_CR47","doi-asserted-by":"publisher","first-page":"E900","DOI":"10.1210\/jc.2014-416747","volume":"100","author":"M Zilbermint","year":"2015","unstructured":"Zilbermint M, et al. Primary Aldosteronism and ARMC5 Variants. J Clin Endocrinol Metab. 2015;100(6):E900\u20139. https:\/\/doi.org\/10.1210\/jc.2014-416747.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1735_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/jhh.2015.9848","volume":"30","author":"P Mulatero","year":"2016","unstructured":"Mulatero P, et al. ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. J Hum Hypertens. 2016;30(6):374\u20138. https:\/\/doi.org\/10.1038\/jhh.2015.9848.","journal-title":"J Hum Hypertens"},{"key":"1735_CR49","doi-asserted-by":"publisher","unstructured":"Joseph JJ, et al.\u00a0The Association of ARMC5 with the Renin-Angiotensin-Aldosterone System, Blood Pressure, and Glycemia in African Americans. J Clin Endocrinol Metab.\u00a02020;105(8). https:\/\/doi.org\/10.1210\/clinem\/dgaa290.","DOI":"10.1210\/clinem\/dgaa290"},{"issue":"1","key":"1735_CR50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12672-019-00375-050","volume":"11","author":"NG Hattangady","year":"2020","unstructured":"Hattangady NG, et al. Molecular and Electrophysiological Analyses of ATP2B4 Gene Variants in Bilateral Adrenal Hyperaldosteronism. Horm Cancer. 2020;11(1):52\u201362. https:\/\/doi.org\/10.1007\/s12672-019-00375-050.","journal-title":"Horm Cancer"},{"key":"1735_CR51","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Rassi-Cruz M, et al.\u00a0Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism. Endocr Relat Cancer.\u00a02021;28(1):1\u201313.\u00a0https:\/\/doi.org\/10.1530\/ERC-20-038451. This study provides novel genetic findings of the genetic etiology of primary hyperaldosteronism.","DOI":"10.1530\/ERC-20-038451"},{"issue":"1","key":"1735_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147590","volume":"11","author":"AR Hong","year":"2016","unstructured":"Hong AR, et al. Genetics of Aldosterone-Producing Adenoma in Korean Patients. PLoS ONE. 2016;11(1): e0147590. https:\/\/doi.org\/10.1371\/journal.pone.0147590.","journal-title":"PLoS ONE"},{"key":"1735_CR53","doi-asserted-by":"publisher","first-page":"11396","DOI":"10.1038\/srep11396","volume":"5","author":"VC Wu","year":"2015","unstructured":"Wu VC, et al. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. Sci Rep. 2015;5:11396. https:\/\/doi.org\/10.1038\/srep11396.","journal-title":"Sci Rep"},{"issue":"4","key":"1735_CR54","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","volume":"73","author":"K Nanba","year":"2019","unstructured":"Nanba K, et al. Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. Hypertension. 2019;73(4):885\u201392. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.12070.","journal-title":"Hypertension"},{"issue":"1","key":"1735_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1507\/endocrj.EJ16-0243","volume":"64","author":"T Okamura","year":"2017","unstructured":"Okamura T, et al. Characteristics of Japanese aldosterone-producing adenomas with KCNJ5 mutations. Endocr J. 2017;64(1):39\u201347. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0243.","journal-title":"Endocr J"},{"issue":"10","key":"1735_CR56","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1210\/js.2018-00097","volume":"2","author":"W Warachit","year":"2018","unstructured":"Warachit W, et al. Prevalence of Somatic KCNJ5 Mutations in Thai Patients With Aldosterone-Producing Adrenal Adenomas. J Endocr Soc. 2018;2(10):1137\u201346. https:\/\/doi.org\/10.1210\/js.2018-00097.","journal-title":"J Endocr Soc"},{"issue":"6357","key":"1735_CR57","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"Lifton RP, et al. A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355(6357):262\u20135. https:\/\/doi.org\/10.1038\/355262a0.","journal-title":"Nature"},{"issue":"22","key":"1735_CR58","first-page":"1109","volume":"95","author":"DJ Sutherland","year":"1966","unstructured":"Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 1966;95(22):1109\u201319.","journal-title":"Can Med Assoc J"},{"issue":"9","key":"1735_CR59","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1210\/jc.2005-0681","volume":"90","author":"M Stowasser","year":"2005","unstructured":"Stowasser M, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90(9):5070\u20136. https:\/\/doi.org\/10.1210\/jc.2005-0681.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1735_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1440-1681.1992.tb00462.x","volume":"19","author":"M Stowasser","year":"1992","unstructured":"Stowasser M, et al. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol. 1992;19(5):319\u201322. https:\/\/doi.org\/10.1111\/j.1440-1681.1992.tb00462.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"8","key":"1735_CR61","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1210\/jc.2008-0594","volume":"93","author":"DS Geller","year":"2008","unstructured":"Geller DS, et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93(8):3117\u201323. https:\/\/doi.org\/10.1210\/jc.2008-0594.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1735_CR62","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1161\/HYPERTENSIONAHA.111.183996","volume":"59","author":"P Mulatero","year":"2012","unstructured":"Mulatero P, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59(2):235\u201340. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.183996.","journal-title":"Hypertension"},{"issue":"11","key":"1735_CR63","doi-asserted-by":"publisher","first-page":"E1861","DOI":"10.1210\/jc.2013-2428","volume":"98","author":"S Monticone","year":"2013","unstructured":"Monticone S, et al. A Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J Clin Endocrinol Metab. 2013;98(11):E1861\u20135. https:\/\/doi.org\/10.1210\/jc.2013-2428.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1735_CR64","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1073\/pnas.1121407109","volume":"109","author":"UI Scholl","year":"2012","unstructured":"Scholl UI, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A. 2012;109(7):2533\u20138. https:\/\/doi.org\/10.1073\/pnas.1121407109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1735_CR65","doi-asserted-by":"publisher","first-page":"E1532","DOI":"10.1210\/jc.2012-1334","volume":"97","author":"E Charmandari","year":"2012","unstructured":"Charmandari E, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97(8):E1532\u20139. https:\/\/doi.org\/10.1210\/jc.2012-1334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1735_CR66","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000358197","volume":"82","author":"M Adachi","year":"2014","unstructured":"Adachi M, et al. Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature. Horm Res Paediatr. 2014;82(2):138\u201342. https:\/\/doi.org\/10.1159\/000358197.","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"1735_CR67","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/cen.13132","volume":"85","author":"A Sertedaki","year":"2016","unstructured":"Sertedaki A, et al. Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion. Clin Endocrinol (Oxf). 2016;85(6):845\u201351. https:\/\/doi.org\/10.1111\/cen.13132.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1735_CR68","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/ajh\/hpz172","volume":"33","author":"AG Maria","year":"2020","unstructured":"Maria AG, et al. Mosaicism for KCNJ5 Causing Early-Onset Primary Aldosteronism due to Bilateral Adrenocortical Hyperplasia. Am J Hypertens. 2020;33(2):124\u201330. https:\/\/doi.org\/10.1093\/ajh\/hpz172.","journal-title":"Am J Hypertens"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-022-01735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-022-01735-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-022-01735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T07:40:42Z","timestamp":1660549242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-022-01735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,16]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1007\/s11886-022-01735-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,16]]},"assertion":[{"value":"7 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Hannah-Shmouni is a member of the Endocrine Hypertension Subcommittee of the Canadian Hypertension Guidelines (Hypertension Canada) and has no relevant disclosures to report. Dr. Stratakis holds patents on the <i>PRKAR1A<\/i>, <i>PDE11A<\/i>, and <i>GPR101<\/i> genes and\/or their function and has received research funding from Pfizer Inc. on the genetics and treatment of abnormalities of growth hormone secretion. Dr. Stratakis is currently employed by ELPEN Pharmaceuticals and has received consulting fees from Sync, Lundbeck, and Sandoz. Dr. Stratakis also reports grant support from the NIH. Dr. Faucz holds a patent on the <i>GPR101<\/i> gene and its function. Dr. Pitsava has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any new human or animal trial study results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}